Pradusinstobart is under clinical development by Lyvgen Biopharma and currently in Phase I for Advanced Malignancy. According to GlobalData, Phase I drugs for Advanced Malignancy does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Pradusinstobart LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Pradusinstobart is under development for the treatment of solid tumors including gastric cancer, metastatic uveal melanoma, head and neck carcinoma, metastatic hepatocellular carcinoma (HCC), metastatic ovarian cancer, soft tissue sarcoma and esophageal cancer. It targets programmed cell death-1 (PD-1). The drug candidate is developed based on the antibody technology platform. It is administered through intravenous and oral route.
Lyvgen Biopharma overview
Lyvgen Biopharma, is a cancer immunotherapy service provider. The company is headquartered in China.
For a complete picture of Pradusinstobart’s drug-specific PTSR and LoA scores, buy the report here.